CJC-1295 + Ipamorelin 10 mg

This listing is a blend. Two separately synthesised peptides are supplied together in a single 10 mg vial: CJC-1295 without DAC, also catalogued as Modified GRF(1-29) or tetra-substituted GRF(1-29), and ipamorelin. The two are chemically unrelated. One is a 29-residue analogue of the N-terminal fragment of human growth-hormone-releasing hormone. The other is a five-residue synthetic ligand for the growth hormone secretagogue receptor GHS-R1a, the receptor that also binds ghrelin. Because the vial contains two molecules, it has no single CAS number, molecular formula, molecular weight or sequence. The certificate of analysis reports each constituent on its own line.

The CJC-1295 backbone is human GRF(1-29) amide carrying four substitutions. The FDA's December 2024 compounding advisory evaluation records the no-DAC form as a 29 amino acid analogue of GHRH with substitutions at positions 2, 8, 15 and 27, citing Jette et al. 2005, and prints the sequence in full: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Aligned against native human GHRH(1-29), the four changes are D-alanine in place of L-alanine at position 2, glutamine in place of asparagine at position 8, alanine in place of glycine at position 15, and leucine in place of methionine at position 27. That same document gives the no-DAC constituent as CAS 446036-97-1, molecular formula C152H252N44O42, molecular weight 3367.95 g/mol. The molecule Jette and colleagues named CJC-1295 adds a lysine at position 30 bearing an N-epsilon-3-maleimidopropionamide group. That maleimide reacts with the free thiol of cysteine-34 on serum albumin to form a covalent bioconjugate, and that linker is what the trade name DAC, or Drug Affinity Complex, refers to. The DAC form is a separate substance with its own registry entry, CAS 446262-90-4, C165H269N47O46, 3647.95 g/mol. Material sold as CJC-1295 without DAC, including this blend, is the backbone without the maleimidopropionyl-lysine.

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is 2-aminoisobutyric acid and D-2-Nal is 3-(2-naphthyl)-D-alanine. Molecular formula C38H49N9O5, molecular weight 711.9 g/mol, CAS 170851-70-4, PubChem CID 9831659, UNII Y9M3S784Z6. Only two of its five residues are standard L-amino acids. Two are in the D configuration, one is the non-proteinogenic Aib, and the C-terminus is amidated rather than a free acid. Both constituents are white lyophilised powders. The FDA evaluation describes CJC-1295 free base as only slightly water-soluble and soluble in 1 percent acetic acid, and the acetate salt of the same peptide as soluble in water at 5 mg per mL, which is why peptides of this class are normally supplied and reconstituted as salt forms rather than as the free base.

The two peptides have separate literatures of very different size and character, and a nomenclature problem sits underneath both. In the peer-reviewed record, CJC-1295 denotes the albumin-binding DAC conjugate. Jette et al. synthesised three maleimido derivatives of human GRF(1-29), bioconjugated them to human serum albumin ex vivo through the free thiol on cysteine-34, and administered them subcutaneously to male Sprague Dawley rats; the tetrasubstituted derivative they designated CJC-1295 produced a 4-fold increase in growth hormone area under the curve over a 2-hour period compared with hGRF(1-29) and was still present in plasma beyond 72 hours (Jette et al., 2005). The FDA's 2024 evaluation reviewed the same literature and concluded that all the human clinical references it could identify appear to have used the DAC form, and that it was unable to identify any study in which the no-DAC free base was administered to humans (FDA, 2024). The no-DAC backbone supplied in this blend therefore has no dedicated human pharmacokinetic literature published under its own name, and the human figures below should be read with that caveat attached.

Teichman et al. ran two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, of 28 and 49 days. After a single injection, mean plasma growth hormone rose 2- to 10-fold for 6 days or more, and mean plasma insulin-like growth factor I rose 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. After multiple doses, mean IGF-I remained above baseline for up to 28 days. No serious adverse reactions were reported (Teichman et al., 2006).

Ionescu and Frohman examined whether the pulsatile pattern of growth hormone release survives continuous receptor stimulation. Healthy men aged 20 to 40 received a single injection at either 60 or 90 micrograms per kilogram, with blood sampled every 20 minutes across an overnight 12-hour period before treatment and again one week after. Basal or trough growth hormone increased 7.5-fold (P less than 0.0001), mean growth hormone levels increased 46 percent (P less than 0.01), and IGF-I increased 45 percent (P less than 0.001). The frequency and magnitude of growth hormone secretory pulses were unaltered, and the two dose groups did not differ from each other. The authors also record a negative result worth reproducing: the IGF-I increases did not correlate with any measured parameter of growth hormone secretion (Ionescu and Frohman, 2006).

Ipamorelin was characterised in 1998 by Raun and colleagues, who concluded it was the first GHRP-receptor agonist whose selectivity for growth hormone release resembled that of GHRH. In primary rat pituitary cells its EC50 was 1.3 plus or minus 0.4 nmol/L with an Emax of 85 plus or minus 5 percent measured against GHRP-6 set at 100 percent, GHRP-6 itself giving an EC50 of 2.2 plus or minus 0.3 nmol/L. Specificity was studied in conscious swine, where none of the secretagogues tested affected FSH, LH, prolactin or TSH, and where ipamorelin did not raise ACTH or cortisol to levels significantly different from those seen after GHRH stimulation even at doses more than 200-fold above the ED50 for growth hormone release; GHRP-6 and GHRP-2, tested alongside, raised both ACTH and cortisol (Raun et al., 1998). Rodent work followed. Johansen et al. gave adult female rats 0, 18, 90 or 450 micrograms per day, each daily amount split across three subcutaneous injections, for 15 days, and measured longitudinal bone growth rates of 42 micrometres per day in the vehicle group against 44, 50 and 52 micrometres per day across the ascending dose groups (P less than 0.0001). In the same study, total IGF-I, IGF binding proteins and serum markers of bone formation and resorption showed no significant change (Johansen et al., 1999).

The one controlled human efficacy trial of ipamorelin that appears in PubMed missed its primary endpoint. Beck et al. enrolled 117 patients undergoing small and large bowel resection, 114 of whom composed the safety and modified intent-to-treat populations, in a proof-of-concept phase 2 study of postoperative ileus. Median time to first tolerated meal was 25.3 hours on ipamorelin against 32.6 hours on placebo, which did not reach statistical significance (P equals 0.15). Overall incidence of any treatment-emergent adverse event was 87.5 percent on ipamorelin and 94.8 percent on placebo. The authors report the compound as well tolerated with no significant differences from placebo in the key and secondary efficacy analyses (Beck et al., 2014). On the combination itself the record is thin. A 2026 narrative review in the American Journal of Sports Medicine reports that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, states that these findings are limited to animal studies, and adds that information on indications, dosing, frequency and duration remains unknown and that significant further research into safety and efficacy is required before definitive recommendations can be made (Mayfield et al., 2026). No controlled human trial of the two peptides administered together is indexed in PubMed, and that review, which covers the pairing directly, cites none. Anything said about the pairing as a unit therefore rests on that single animal report plus the two separate literatures above.